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ABSTRACT Monitoring of Plasmodium falciparum sensitivity to antimalarial drugs in
Africa is vital for malaria elimination. However, the commonly used ex vivo/in vitro
50% inhibitory concentration (IC50) test gives inconsistent results for several antima-
larials, while the alternative ring-stage survival assay (RSA) for artemisinin derivatives
has not been widely adopted. Here, we applied an alternative two-color flow
cytometry-based parasite survival rate assay (PSRA) to detect ex vivo antimalarial tol-
erance in P. falciparum isolates from The Gambia. The PSRA infers parasite viability
by quantifying reinvasion of uninfected cells following 3 consecutive days of drug
exposure (10-fold the IC50 of drug for field isolates). The drug survival rate is ob-
tained for each isolate from the slope of the growth/death curve. We obtained para-
site survival rates of 41 isolates for dihydroartemisinin (DHA) and lumefantrine (LUM)
out of 51 infections tested by ring-stage survival assay (RSA) against DHA. We also
determined the genotypes for known drug resistance genetic loci in the P. falcipa-
rum genes Pfdhfr, Pfdhps, Pfmdr, Pfcrt, and Pfk13. The PSRA results determined for 41
Gambian isolates showed faster killing and lower variance after treatment with DHA
than after treatment with LUM, despite a strong correlation between the two drugs.
Four and three isolates were tolerant to DHA and LUM, respectively, with continuous
growth during drug exposure. Isolates with the PfMDR1-Y184F mutant variant
showed increased LUM survival, though the results were not statistically significant.
Sulfadoxine/pyrimethamine (SP) resistance markers were fixed, while all other anti-
malarial variants were prevalent in more than 50% of the population. The PSRA de-
tected ex vivo antimalarial tolerance in Gambian P. falciparum. This calls for its wider
application and for increased vigilance against resistance to artemisinin combination
therapies (ACTs) in this population.
KEYWORDS Plasmodium falciparum, drug tolerance, flow cytometry, ex vivo,
antimalarial agents, artemisinin combination therapies, drug resistance, ex vivo
survival rates, genotypes
There has been a substantial decline in malaria morbidity and mortality in sub-Saharan Africa (sSA) over the past decade (1). This decline was mainly driven by the
scaling up of control interventions such as long-lasting insecticidal nets and clinical
case management with artemisinin combination therapy (ACT) (1). Currently, ACTs are
used in countries in regions of endemicity for the treatment of clinical malaria,
specifically, for individual chemoprevention in mass treatment campaigns (2). These
interventions increase pressure on the parasites, which could result in the emergence
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of resistance to both partner drugs and to artemisinin derivatives as confirmed previ-
ously in Southeast Asia (3, 4) and in reports of delayed parasite clearance in Africa (5).
Currently, the WHO recommends regular efficacy testing of the locally used anti-
malarials in humans, complemented by in vitro (laboratory-based) assessment of
parasite growth in response to drug exposure (6). Comparing the in vitro efficacies of
ACTs is complex as the components have different mechanisms of action (5). Moreover,
most of the existing drug susceptibility assays were developed when treatment was
based on monotherapies (7, 8). The most common assays are based on the 50%
inhibitory concentrations (IC50s) required to inhibit parasite growth by half, under a set
of experimental conditions (9, 10). This approach is sensitive to variations in the drug
concentrations used with inconsistency in data analysis (11). IC50 assays also do not
assess the temporal course of parasite viability following exposure and are not suited
to use with artemisinin derivatives with characteristically shorter half-lives (9).
New in vitro methods assessing the efficacy of fast-acting drugs such as the
ring-stage survival assay (RSA) (12), the piperaquine survival assay (PSA) (13), and the
parasite viability fast assay (PVFA) (14) are now available. RSA and PSA determine
parasite survival following drug exposure and withdrawal, while the PVFA aims at
discriminating fast-acting antimalarial drugs by assessing parasite killing kinetics over
time. There are still critical gaps in these assays. The RSA was designed solely for
analysis of fast-acting drugs and therefore cannot be used for analysis of slow-acting
antimalarials with longer half-lives (15). The PVFA has been used only in antimalarial
development for screening candidate drugs.
Besides in vitro assessment of drugs, molecular surveillance is recommended to
monitor the emergence and spread of resistance by determining the proportion of
isolates in a given population with resistance-associated alleles (16, 17). While the kelch
13 molecular markers of artemisinin resistance have not been identified in sSA (18),
alleles in PfCRT and PfMDR1 showing resistance to both currently used and previously
used drugs, including partners in ACTs, are in circulation (19). For instance, the use of
lumefantrine (LUM) in the ACT artemether-lumefantrine (AL) has been associated with
an increase in copy numbers, the frequency of N86 allele, and the N86/184F/D1246
haplotype of PfMDR1 (20–25). Additionally, sulfadoxine/pyrimethamine (SP) is used in
seasonal malaria chemoprevention (SMC) and as an intermittent preventive treatment
in pregnancy (IPTp), selecting for mutant PfDHFR and PfDHPS alleles (26). Combining
molecular surveillance with in vitro surveillance can therefore provide an early warning
signal indicating the emergence of drug-tolerant parasites. This is critical for a parasite
population that is exposed to substantial pressure represented by drug and vector
control interventions such as in The Gambia, where malaria transmission and preva-
lence are low to very low. The Gambia together with neighboring Senegal, is driving for
malaria elimination by deploying SMC, while mass drug treatments with ACTs are being
contemplated.
Therefore, the goal of this study was to evaluate a parasite survival rate assay (PSRA)
to estimate the ex vivo drug sensitivity of P. falciparum from The Gambia to the
currently used ACT (AL). The PSRA mimics 3 days of exposure to an ACT and determines
parasite survival rates over this period. The assay assesses the survival and reinvasion
potential of parasites following exposure to LUM and dihydroartemisinin (DHA), which
are prototypes of the slow- and fast-acting components of ACTs used in most countries
where malaria is endemic. The approach offers significant advantages over the stan-
dard IC50 determination assay due to its higher sensitivity in measuring parasite
viability based on the production of invasive merozoites after drug exposure, repre-
senting an index of drug susceptibility or tolerability.
RESULTS
Plasmodium falciparum isolates collected from patients with uncomplicated malaria
cases recruited across the malaria transmission season in 2017 from Western Gambia
were analyzed. A total of 79 of 170 (46.5%) isolates had a parasitemia level of 0.5%,
and these were set up for both PSRA and RSA. Analysis data were obtained for 41 (52%)
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and 51 (64.6%) samples, which had a drug-free ex vivo growth rate of 1% for PSRA
and RSA, respectively. Apart from the field isolates used in this study, the PSRA was
tested against a panel of previously characterized isolates, including an artemisinin-
resistant parasite line: MR4-1241 with the K13 I543T mutation.
Ring stage survival rates of field isolates by microscopy and flow cytometry.
Ring-stage survival rates of 51 isolates were determined using conventional microscopy
per the initial RSA protocol (12), which was modified here by the use of uninfected red
blood cells (uRBC) prelabeled with 7-hydroxy-9H-(1,3-dichloro-9, 9-dimethylacridin-2-
one) succinimidyl ester (DDAO-SE) (uRBCDDAO-SE) and SYBR green I for flow cytometric
analysis. Following pulse exposure to DHA, 31 isolates (61%) had surviving parasites
observed by microscopy at levels ranging from 0.05% to 1.2% (Fig. 1a). Flow cytometric
counting of reinvasion in prelabeled uRBCs was more sensitive, showing all isolates to
have post-drug exposure survival rates that ranged from 0.14% to 1.53%. The mean
survival rates determined by flow cytometric analysis were significantly higher than
those determined by microscopy (P  0.0001). Despite this, there was a strong positive
FIG 1 (a) Percent ring survival of 51 isolates determined using conventional microscopy to assess viable parasites and flow cytometry to assess the number of
reinvaded parasites following pulse exposure and withdrawal of DHA with RSA. Each point on the plot represents an isolate. The median survival rates of the isolates
for each method are shown as the red broken lines. t test statistics gave a P value of 0.0001 using the Wilcoxon rank sum test. (a and b) Correlation analysis of percent
ring survival determined using flow cytometry and microscopy with a Pearson correlation coefficient of R  0.83 and a P value of 0.0001 (b) and correlation analysis
of percent ring survival using RSA and parasite survival rates using PSRA (c). The Pearson correlation coefficient gave an R value of 0.53 and a P value of 0.00036. (d)
Distribution of the parasite survival rates of 41 isolates treated with DHA and LUM at 3 time points over 72 h with PSRA. Each point shows the rate at which each isolate
survived following drug exposure with reference to a DMSO-treated control. The red dotted lines represent the median survival rates for both drug treatments with
P  0.35. A P value of 0.05 represents statistical significance. All ex vivo assays were performed in triplicate.
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correlation between the two analysis methods (R  0.83, P  2.7  1014) (Fig. 1b).
However, the isolates with the highest ring survival rates as determined by flow
cytometry were not the same as those observed by microscopy. Based on flow
cytometry only, percent ring survival after 6 h of exposure to 700 nM DHA significantly
correlated with parasite survival rates following PSRA (R  0.53, P  0.00038) (Fig. 1d).
Overall, the median cumulative rates of survival over the 72 h of exposure were not
significantly different between DHA (0.051% to 0.029%) and LUM (0.048% to
0.037%) (P  0.35), though the responses to LUM had a wider distribution (Fig. 1d).
P. falciparum ex vivo survival decreases with longer drug exposure. Comparing
log values of survival rates between isolates with different durations of drug exposure,
the overall survival rate declined with increased exposure time for both drugs, whereas
there was an increasing growth trend in the drug-free group over time (Fig. 2). The
mean differences between the treatment and control groups were always statistically
significant and increased with time, as the treatment groups appeared to show a
marked decline in predicted survival, particularly after 72 h (see Fig. S1 in the supple-
mental material). Pairwise comparison between the drug-treated groups and the
drug-free group showed significant differences at all three time points (Table 1). Using
24 h as the reference, differences in predicted responses were seen for both DHA and
FIG 2 (a and b) Individual trajectories of 41 isolates following exposure to (a) DHA and (b) LUM relative to DMSO-treated controls at the 24-, 48-, and 72-h time
points. A linear mixed-effect model was used, and a linear trend was fitted for each isolate across time points. The dotted blue and red lines show the isolates
with decreasing and increasing responses over time, respectively. The thick blue and red lines represent the mean log responses of isolates with decreasing
and increasing responses, respectively. (c) Mean predicted parasite responses of all isolates following exposure to DHA (red broken line), LUM (blue broken line),
and DMSO control (gray broken line), with the standard errors of the means (SEM) shown as bars. (d) Correlation between parasite survival rates of isolates
treated with DHA and LUM with R  0.77 and a P value of 0.001. All ex vivo assays were performed in triplicate.
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LUM at 72 h after drug exposure. The predicted responses seen at 48 h were not
statistically significantly different from those seen at 24 h. This could have been due to
the exponential increase in the levels of merozoite-infected RBCs seen following a
complete P. falciparum growth cycle (27), potentially resulting in the high response
levels seen at 48 h in the control group (Fig. 2c).
Distribution of PSRA sensitivities to AL. We derived individual responses to each
drug by fitting a linear model to the differences in predicted responses between the
drug-treated group and the control group with time. These ex vivo parasite survival
rates ranged from 0.051 to 0.029 for DHA and from 0.048 to 0.037 for LUM. The
majority of isolates had a negative slope with consistently reducing survival with time
(Fig. 2a and b). This was seen for 30 isolates for DHA and 35 for LUM, representing 73%
and 85% of treated isolates, respectively. In contrast, 27% (11/41) and 15% (6/41) had
a net increase in growth despite 72 h of exposure to DHA and LUM, with predicted
responses under drug conditions similar to or higher than those determined for the
controls treated with dimethyl sulfoxide (DMSO) (Fig. 2a and b; see also Fig. S2a and b).
The overall responses and rates of growth decline were higher for DHA than for LUM
(Fig. 2c). However, the survival rates seen with DHA and LUM treatment showed a
strong positive correlation (R  0.77, P  5.4e09), (Fig. 2d).
Consistent clusters of survival rate patterns corresponding to both DHA and
LUM. We identified four patterns of responses based on the growth-versus-time curve for
both drugs (Fig. 3). The most common pattern was a continuous decline in survival with an
increase in time of exposure. This first group of isolates, defined as representing linear
decrease (“” in Fig. 3), represented 46% (19/41) and 51% (21/41) of isolates tested
against DHA and LUM, respectively. The second group of isolates had a peak in growth at
48 h of drug exposure (““), and these represented 19.5% (8/41) and 22% (9/41) of
isolates tested, respectively. The third group consisted of isolates with consistently linear
increases (“”) despite drug exposure, with 9.75% (4/41) and 7.3% (3/41) identified for
DHA and LUM, respectively, and the fourth pattern consisted of isolates with the lowest
survival time point at 48 h (“”), representing 24% (10/41) and 20% (8/41) of isolates,
respectively. These patterns did not correlate with initial parasitemia (Fig. S4) or with other
patient demographic information.
Frequencies of drug resistance alleles in western Gambia. We obtained geno-
types for at least 39 isolates for pfcrt C72/M74/N75/K76, pfmdr1 N86, pfmdr1 Y184,
TABLE 1 Effect of drug exposure on predicted responses of the treatment groups (DHA,
LUM, and DMSO control) and exposure times (24, 48, and 72 h) for P. falciparum isolates
analyzed by PSRAa
Treatment group Difference (95% CI) P value
DHA vs control
24 h 0.68 (0.90, 0.47) <0.0001
48 h 1.03(1.25, 0.81) <0.0001
72 h 1.20 (1.42, 0.99) <0.0001
24 h 0.31 (0.52, 0.09) 0.005
LUM vs control
48 h 0.62 (0.84, 0.41) <0.0001
72 h 0.99 (1.21, 0.77) <0.0001
48 h vs 24 h
Control 0.25 (0.01, 0.48) 0.04
DHA 0.10 (0.33, 0.13) 0.39
LUM 0.07 (0.30, 0.16) 0.57
72 h vs 24 h
Control 0.14 (0.13, 0.42) 0.31
DHA 0.38 (0.65, 0.10) 0.007
LUM 0.54 (0.81, 0.27) 0.0001
aCI, confidence interval; DHA, dihydroartemisinin treatment; LUM, lumefantrine treatment; control, DMSO
treatment. Bold values indicate P values representing statistically significant results determined by pairwise
comparisons.
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pfdhps S436/A437, pfdhfr N51/C59, and pfk13 C580 (Table 2; see also Fig. 4). The pfcrt
mutant haplotype was found in 79% of the isolates, with 2% mixed infections. Among
those isolates, 93% were wild type for pfmdr1 N86 and 5% mixed, while 57% were
mutant for pfmdr1 Y184 and 12% mixed. For antifolate markers, 90% of the isolates had
mutation variants at pfdhps S436/A437 whereas all of the isolates were mutated for
FIG 3 Grouped profiles of 41 isolates following exposure to DHA and LUM at 24, 48, and 72 h with PSRA. Each point in the individual
plots represent the difference between the predicted response of the (a) DHA-treated and control isolates and (b) LUM-treated and
control isolates. The connecting lines give an indication of the response pattern of each isolate. The isolates are grouped based on
their response profiles. (i) Linear decrease (). (ii) Nonlinear decrease/increase (). (iii) Linear increase (). (iv) Nonlinear
increase/decrease ().
TABLE 2 Allele frequencies of drug resistance genes for 41 parasite isolates with drug
phenotypic data (PSRA and RSA)a
Gene Allele(s) Codon(s) Frequency
pfcrt C72, M74, N75, K76 CMNK (wild type) 0.17
CIET (mutant) 0.79
CMNK/CIET (mixed) 0.02
pfmdr1 N86 N (wild type) 0.93
Y (mutant) 0
N/Y (mixed) 0.05
Y184 Y (wild type) 0.29
F (mutant) 0.57
Y/F (mixed) 0.12










pfk13 C580 C (wild type) 1
Y (mutant) 0
apfcrt, P. falciparum chloroquine resistance transporter gene; pfmdr1, P. falciparum multidrug resistance gene
1; pfdhps, P. falciparum dihydropteroate synthase gene; pfdhfr, P. falciparum dihydrofolate reductase gene;
pfk13, P. falciparum kelch 13 gene.
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pfdhfr N51/C59. We excluded the analysis for the pfdhfr alleles corresponding to IT/NC
as the results of scoring of the melting curves were ambiguous, showing up to 55% of
mixed-allele calls. PfK13 C580 was wild type for all isolates. Given the almost fixed
frequencies of either the wild type or the mutant at these tested loci, no association
with the PSRA patterns could be determined. However, for pfmdr1 codon 184, higher
LUM responses were observed for isolates with the 184F mutant allele though the
mean differences between these isolates and the isolates with the Y184 wild-type
variant were not significant (Fig. 4c, panel ii).
DISCUSSION
This report describes the rates of ex vivo susceptibility of natural P. falciparum
isolates from The Gambia, where transmission has declined and where we have seen
increasing ex vivo tolerance of P. falciparum parasites to LUM by IC50 as well as modest
(26%) rates of parasite survival following exposure to DHA by ring-stage survival assay
(RSA) (19). These rates were obtained against DHA and LUM with a flow cytometry-
based parasite survival rate assay (PSRA), with potential application to other drugs and
antimalarial candidates. The potency of these drugs depends on the drug concentra-
tions used and the length of exposure, with the assumption that cytotoxicity occurs
FIG 4 (a) Allele frequencies of 41 field isolates for the following drug resistance genes: pfcrt C72/M74/N75/K76, pfmdr1 N86, pfmdr1 Y184, pfdhps S436/A437,
and pfk13 C580. (b and c) Rates of parasite survival of (b) DHA and (c) LUM treatment for isolates with wild-type, mutant, and mixed alleles corresponding to
pfcrt C72/M74/N75/K76, pfmdr1 Y184, and pfdhps S436/A437. Each point in the graphs represents the parasite survival rate of an isolate. The broken red lines
indicate the median survival rates of the isolates with the same alleles.
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when parasites are exposed to the active component of the drug for a prolonged time
(28). Here, we used drug concentrations that are 10-fold higher than the median IC50
of the respective drugs obtained from the assessment of field isolates from western
Gambia in 2015 (19). The use of 10-fold-higher drug concentrations, though those
concentrations are much lower than serum concentrations, proved to be optimal to
determine the rate of killing by slow-, medium-, and fast-acting drugs. This concentra-
tion is suboptimal, allowing a gradual effect of the drugs on the parasites (29).
The PSRA provided several advantages over the IC50 and RSA assays; it determines
the effect of drugs over 72 h of exposure and measures both parasite growth and
viability by determining reinvasion even at low parasite densities. Unlike the RSA, there
is no requirement for assaying early rings, which can be difficult to obtain from natural
isolates from malaria patients, thereby eliminating the need for further stressing
isolates by synchronizing them with sorbitol. Similarly to the in vivo parasite clearance
rate used for determining the efficacy of artemisinin derivatives (30), the PSRA deter-
mines clearance rates from the rate of ex vivo inhibition of growth over 72 h of drug
exposure. This duration of exposure allows rings that emerge from tolerant isolates
over the first cycle (48 h) to experience another round of drug exposure for 24 h,
followed by recovery in drug-free medium. The overall outcome is the kinetics of
parasite killing by the test drug over 72 h. This assay is therefore a variant of the PVFA
(14, 29). Like the PVFA, the PSRA does not assess parasite metabolic activity or other
parasite molecules to quantify survival or death indirectly (14). It quantifies viability
from a direct count of the viable merozoites that emerge from drug-exposed schizonts
and invade prestained uninfected RBCs (uRBCDDAO-SE). Flow cytometry provided in-
creased sensitivity by enabling individual counting of cells and distinguishing new
autologous and heterologous infected cells. With a 2-to-1 ratio of RBCDDAO-SE to
nonlabeled RBCs, higher numbers of prelabeled RBCs are present, skewing reinvasion
to occur in these cells. As merozoites emerge after drug exposure, active reinvasion is
proof of viability. This gives a good estimate of the number of parasites that survive
following drug exposure. The rate of death is therefore intrinsically linked to the level
of drug tolerance exhibited by each isolate. Autologous reinvasion of unlabeled RBCs
is excluded from the analysis as they cannot be differentiated from dead and arrested
cells. The PSRA uses a concentration of drug that is much lower than that used in the
RSA but that is potent enough to kill isolates and to induce the delayed-clearance
phenotype in the RSA control isolate (MRA-1241). Hence, there was a high positive
correlation between PSRA and the modified flow cytometry-based RSA. With strong
correlation with microscopy but improved throughput, flow cytometry-based RSA and
PSRA should allow robust detection of emerging drug tolerance in natural isolates.
Future and wider application of this method is warranted in Africa, where drug pressure
is substantial. This is the case for The Gambia, where the artemisinin combination
therapy AL is used as the first-line treatment and other ACTs are being considered for
mass administration after several clinical trials.
Most of the isolates tested by PSRA in The Gambia had decreasing parasite survival
with increasing days of exposure to drugs. However, four isolates exposed to DHA and
three exposed to LUM continued to grow and were considered potentially tolerant,
with one isolate surviving in the presence of both drugs. More isolates would have
been classified as tolerant if all those that showed a rebound of growth at 72 h were
included. These results suggest a state of reduced drug sensitivity, allowing parasite
growth and reinvasion to occur in the presence of sublethal drug concentrations (31).
The six surviving isolates could be on a path toward a persistent state of drug
insensitivity that may result in resistance (32) and should be closely monitored. Ex-
tending the assay time to 96 h might also reveal clearer response profiles for the
isolates with nonlinear responses over the 72-h period. Importantly, the weak correla-
tion between initial patient parasitemia and parasite response suggests that the
responses seen were not driven by the rate at which the parasites grew in the patient
(in vivo). Most isolates had similar response patterns for the two drugs, and their
survival rates correlated positively. This might be an indication of common mechanisms
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that enable survival of parasites following exposure to several drugs, a factor that could
lead to multidrug resistance. Multidrug resistance to artemisinin derivatives and part-
ners has been confirmed in Southeast Asia (33). We have already shown a consistent
increase of LUM tolerance in The Gambia between 2012 and 2015 (19). In the same
study, 26% of the isolates in the 2015 population from western Gambia showed viable
parasites by microscopy-based RSA for DHA. The presence of surviving parasites in this
current study, though at different proportions in the two assays, suggests a sustained
low level of DHA tolerance and requires further investigation. These parasites survived
and replicated under conditions of exposure to a high concentration of DHA and a
prolonged period of DHA pressure with RSA and PSRA, respectively. The rate of malaria
transmission in western Gambia has dropped drastically in the last decade, with
prevalences of infection of lower than 5% overall and 1% for children under 5 years of
age. Despite this, various ACTs remain widely available and accessible through private
and public vendors. While it is officially required that ACTs should be prescribed only
upon a positive malaria diagnosis, adherence to that policy is sporadic given the
regularly low level of availability of rapid diagnostic test kits. We can therefore spec-
ulate that the emergence of tolerant parasites is being driven by high drug pressure
against low transmission, which is hypothesized to be one of the main drivers in the
emergence of antimalarial drug resistance in Southeast Asia. This calls for improved
vigilance across Africa as elimination programs are implemented. ACT resistance has
been shown to emerge on a backbone of known genes conferring drug resistance,
including Pfmdr1 and Pfcrt selected by LUM treatment. The WHO recommends surveil-
lance for known and emerging markers of resistance in natural populations.
We genotyped the isolates assayed for alleles at Pfmdr1, Pfcrt, Pfdhfr, Pfdhps, and
Pfk13 loci that have been implicated in quinoline, antifolate, or artemisinin resistance.
We found high levels of resistance loci against the antifolates, an expected result given
the use of SP by SMC and IPTp. We also found high levels of Pfmdr1 N86, the wild-type
allele selected by LUM treatment, a result aligning with what we had shown before for
this population (19). In contrast, the Pfcrt 72-76 mutant haplotype was in over 80% of
isolates, indicating continuous selection by chloroquine. Approval of the use of chlo-
roquine for treatment of malaria had been withdrawn, raising the issue of which drugs
are driving selection at Pfcrt but not Pfmdr1 (34). Selection of Pfcrt may be driven by
amodiaquine, which is available in combination with artesunate and accessible from
private vendors in The Gambia and is the ACT of choice in neighboring Senegal (21),
with whom there is significant human migration. We expect to gain more insights into
this considering the current extensive temporal and spatial genome sequencing being
performed for these parasite populations. Given the high levels of mutant or wild-type
alleles present at drug resistance genes, an analysis of genetic association for the four
different parasite PSRA profiles was not possible. However, higher survival rates against
LUM were seen for isolates with the mutant variant at Pfmdr1 184F though the rates
were not significantly different from the distribution seen in isolates with wild-type
alleles. We assume that the responses observed for samples carrying multiple strains
represent combined effects of the different strains present and that the six isolates that
survived following exposure to either of the two drugs have specific molecular signa-
tures influencing their phenotypes which should be further investigated. Despite the
number of isolates showing growth after 72 h of exposure to DHA, no mutant alleles of
Pfk13 C580 were found in the population. Artemisinin-associated kelch 13 variants are
rare in African populations, but high frequencies of other nonsynonymous single
nucleotide polymorphisms (SNPs) on Pfk13 (kelch propeller domain) had been ob-
served for isolates from The Gambia (35). These data further buttress the idea of a need
for routine and in-depth surveillance of this population.
This report highlights early signs of ex vivo drug tolerance of parasites from western
Gambia to the most common ACT components. These signs were derived by PSRA,
which provides a significant advancement in approaches implemented for the deter-
mination of parasite susceptibility. A wider application of this approach across sSA to
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distinguish drug tolerance and resistance will support current and future chemopre-
vention and chemotherapeutic strategies against malaria.
MATERIALS AND METHODS
Sample collection. Ethical clearance for this study was obtained from The Gambia Government/
Medical Research Council Unit in The Gambia (MRCG) Joint Ethics committee and further approved by
the Gambian Ministry of Health. The study was conducted as part of a therapeutic efficacy study (TES)
of AL in collaboration with the National Malaria Control Program (NMCP) at the Brikama Health Centre
(Western Gambia) in 2017. Patients were included in the study following diagnosis of P. falciparum
infection with a parasite density of at least 1,000/l. Informed consent or assent was obtained from
eligible patients. Two milliliters of venous blood samples were collected into EDTA tubes at day 0 of the
TES and blood spots (BS) made on Whatman filter papers (Scientific Laboratory Supplies). Filter papers
were air dried and stored in sealed sample bags with silica gel desiccants. Samples were transported on
ice to the MRCG at the London School of Hygiene and Tropical Medicine (LSHTM) culture facility and
processed within 4 h of collection.
Parasite processing for drug assays. Thin blood smears were made for all samples to identify
parasite life cycle stages. For each sample, 50 l was used to estimate parasite density using a C6 flow
cytometer (BD Accuri; BD Biosciences) after DNA staining was performed with SYBR green I DNA
intercalating dye (Applied Biosystems). To eliminate white blood cell populations from the analysis,
gating was done on the red blood cell (RBC) population using only forward and side scatter parameters
followed by gating of the SYBR green 1-positive population, which effectively delineates parasitized
RBCs. Plasma was separated from blood cells following centrifugation for 5 min at 1,500 rpm. Equal
volumes of incomplete media (RPMI 1640 [Sigma-Aldrich, United Kingdom] supplemented with 35 mM
HEPES [Sigma, St. Louis, MO], 24 mM NaHCO3, 1 mg/liter of hypoxanthine [Sigma], and 5 g/ml of
gentamicin [Gibco-BRL]) were added to the cell pellet and layered on 6 ml of LymphoPrep (Axis Shield,
United Kingdom). The layered sample was centrifuged for 20 min at 2,500 rpm, and leukocytes were
aspirated. The RBCs were washed thrice by resuspending the pellet in incomplete media and centrifuged
for 5 min at 1,500 rpm. The washed pellet was resuspended in growth medium (incomplete medium with
0.5% AlbuMAX [Gibco-BRL]). The parasitemia was normalized to 0.5% (1,000 parasites/l) for all samples
with parasitemia levels higher than 0.5% and 2% hematocrit using uninfected type O-positive (O)
heterologous RBCs prior to PSRA and RSA. Four laboratory-adapted strains (3D7, Dd2, and MRA-1239,
which are sensitive to both LUM and DHA, and MRA-1241, which is sensitive to LUM but resistant to DHA)
were used as internal controls. The isolates were routinely cultured with fresh O RBCs and maintained
at 2% hematocrit with growth media under standard incubation conditions of 37°C, 90% N2, 5% O2, and
5% CO2. All laboratory-adapted strains were synchronized twice with 5% D-sorbitol to obtain 80% ring
stages prior to assay setup. A total of 170 samples were obtained from Brikama Health Centre in 2017.
Parasite survival rate assay (PSRA). The parasite survival rate assay is based on reinvasion of
surface-labeled uninfected O RBCs (uRBC) by merozoites emerging from ruptured schizonts that
developed after drug exposure of infected samples. This represents a modification of a previously
described protocol (14). Here, target uRBCs were prelabeled with the amine-reactive fluorescent dye
7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one) succinimidyl ester (DDAO-SE; Invitrogen) (10 M),
a Far Red cell dye, as previously described (36). A 2% hematocrit suspension of the uRBCs in incomplete
media with 10 M DDAO-SE was made and incubated at 37°C for 2 h with shaking. The suspension was
washed once, resuspended with incomplete media, and reincubated for a further 30 min. Suspensions
of DDAO-SE-labeled uRBC (uRBCDDAO-SE) were washed and reconstituted with growth media to achieve
a final hematocrit of 2%.
PSRAs were set up using laboratory isolates of 80% rings (in vitro) and field isolates within 4 h of
sample collection (ex vivo). The assays were done in triplicate to determine levels of sensitivity to
concentrations that were 10-fold higher than the median IC50 of the respective drugs determined in a
previous study (19). Briefly, 100 l of parasite suspension at 0.5% parasitemia and 4% hematocrit was
added to 48-well microtiter plates precoated with 100 l of the corresponding drugs at twice the target
concentration [(10-fold median IC50)  2]. This resulted in a final drug concentration of 10-fold median
IC50 of DHA (8.1 nM) and LUM (398 nM) at 2% hematocrit. A no-drug control, substituted with 0.1%
dimethyl sulfoxide (DMSO [Sigma-Aldrich, United Kingdom]), was assayed for each sample. The samples
in the microtiter plates were incubated for 24, 48, or 72 h under standard incubation conditions. Drugs
were refreshed every 24 h after washing the cells by incubating twice for 5 min with incomplete media.
Fifty microliters of the drug-free suspension was transferred to a fresh 96-well microtiter plate containing
100 l of uRBCDDAO-SE (1-in-3 dilution), which was further incubated for 48 h (Fig. 5).
Each sample was then washed and counterstained with a 1:10,000 dilution of SYBR green
I–phosphate-buffered saline (PBS). For this, 100 l of diluted stain solution was added to each assay well
of the microtiter plate and incubated in the dark at room temperature with shaking for 20 min. Stained
cells were washed twice and resuspended with 200 l of PBS. A further 1-in-4 dilution with PBS was done
prior to flow cytometry counting using a BD Accuri C6 flow cytometer. For acquisition, the fluorescence
emission peaks for SYBR green I and DDAO-SE were set at 520 nm and 657 nm for the green and red
channels, respectively. For each assay well, 100,000 events were acquired, and data were analyzed using
BD Accuri C6 software.
Ring-stage survival assay (RSA). A modification of the RSA protocol (12, 37) was carried out to
assess the reinvasion potential of parasites exposed to 700 nM DHA, replacing microscopy with two-color
flow cytometry similarly to the PSRA protocol described above. Leukocyte-depleted infected RBCs (iRBCs)
were set up in duplicate at 0.5% parasitemia and 2% hematocrit. Each isolate was exposed to 700 nM
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DHA and 0.1% DMSO as a control for exactly 6 h under standard incubation conditions. DHA and DMSO
were then washed off using incomplete media and parasites resuspended with drug-free growth media.
Fifty microliters of this suspension was added to 100 l uRBCDDAO-SE in a separate 96-well microtiter plate,
and both plates were incubated for a further 66 h. Thin blood smears were then made and stained with
Giemsa following the standard RSA protocol. Ring-stage survival rates were determined microscopically
using the initial parasitemia before drug exposure (initial parasitemia: INI), the DMSO control (nonex-
posed [NE]), and DHA exposure (DHA). Ring-stage survival was calculated for isolates with a growth rate
of 1% using the following published formula:
Percent survival %  DHA/NE  100
The cells incubated with uRBCDDAO-SE were counterstained with SYBR green I as described above and
acquired using a BD Accuri C6 flow cytometer to determine parasite reinvasion rates.
Genotyping of selected drug resistance loci. Genotyping was done by locus-specific high-
resolution melting (HRM) assays with parasite DNA extracted from filter-paper-dried blood spots (DBS).
To recover parasite DNA, DBS were punched onto plates containing 96 deep wells, using punchers and
forceps that were rinsed in 1% bleach and alpha-Q water after each sampling step to limit cross-
contamination. For each plate, 4 negative and 4 positive controls were included. Genomic DNA (gDNA)
was manually extracted using a QIAamp 96 DNA blood kit (Qiagen, Hilden, Germany) and the manu-
facturer’s instructions. The DNA concentrations of the eluates were quantified using a NanoDrop 1000
spectrophotometer (Thermo Scientific) and stored at –20°C until use. One micromolar volume of gDNA
of approximately 10 pg (1 ng/l) was used for genotyping assays. HRM genotyping reactions were
performed for alleles pfcrt C72/M74/N75/K76, pfmdr1 N86, pfmdr1 Y184, pfdhps S436/A437, pfdhfr
N51/C59, and pfk13 C580 on a LightCycler 96 real-time PCR system (Roche). The primers and probes used
for PCRs with a 2.5 LightScanner master mix (Biofire) were as previously described (38). Each reaction
mixture had final forward and reverse primer concentrations of 0.05 M and 0.2 M, respectively
(asymmetric PCR) and a 0.2 M concentration for allele-specific probes. The PCR conditions and analysis
method used were as previously described (38).
Statistical analysis of drug survival rates. The analysis was aimed mainly at evaluation of the
effects of drug exposure by determination of the magnitude of the decline in growth caused by
reinvasion according to the time of exposure compared to drug-free controls, i.e., LUM-treated isolates
versus no-drug control and DHA-treated isolates versus no-drug control. We also aimed to explore
FIG 5 Schematic representation of ex vivo parasite survival rate assay. (Step 1) iRBCs at 0.5% parasitemia and 2% hematocrit are incubated with 10-fold median
IC50s of dihydroartemisinin and lumefantrine for 24, 48, and 72 h. (Step 2) uRBCs are labeled with the intracellular dye DDAO-SE (uRBCDDAO-SE). (Step 3) Drugs
are washed off from the reaction mixtures from step 1 every 24 h, aliquots taken, and drugs replenished. (Step 4) Postexposure drug-free aliquots are incubated
with 2 uRBCDDAO-SE for a further 48 h. (Steps 5 and 6) The aliquots are then counterstained with SYBR green I for flow cytometric analysis (step 5), and 100,000
cells are acquired (step 6). (Step 7) Doubly positive stained cells are analyzed.
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patterns of variation in response to drug exposure between isolates. To first assess the effect of time of
exposure on survival (growth), the reinvasion rate values were log-transformed for normality and the
resulting values were used to generate descriptive statistics representative of the responses at each time
point. Linear mixed-effect models were then fitted to examine the heterogeneity in drug susceptibility,
allowing for interaction between time and drug treatment group (LUM or DHA) with random effects on
subjects. Since there were three discrete time points of measurement, with the data serving as an
indication of a potential nonlinear relationship between treatment response and time, we used time as
a categorical variable to determine differences in the effects of treatment performed for 48 and 72 h
against 24 h as the reference. As such, we were able to examine the effect of longer exposure. To explore
the differences in susceptibility to each drug per isolate, we first determined the drug effect from analysis
of the difference between drug-exposed isolates and no-drug control isolates at each time point. We
then fitted a linear trend across time points for each isolate, deriving patterns of individual growth decay
slopes. These estimated slopes represent individual parasite survival (or death) rates. On the basis of the
derived decay patterns (individual trajectories), an isolate was assigned to one of the following four
classes: linear decrease (), linear increase (), nonlinear increase/decrease () and nonlin-
ear decrease/increase (). In addition, we assessed the relationship between individual trajectories
and their corresponding genotypes. All analyses were performed using the R package (RStudio version
1.2.5001) and Stata 14 (StataCorp, College Station, TX, USA). A P value of 0.05 was considered
significant. Other plots were explored using Prism (GraphPad Prism version 7.0a).
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